Modulation of mutant krasG12D-driven lung tumorigenesis in vivo by gain or loss of PCDH7 function

Xiaorong Zhou, Mahesh S. Padanad, Bret M. Evers, Bethany Smith, Nicole Novaresi, Shruthy Suresh, James A. Richardson, Emily Stein, Jingfei Zhu, Robert E. Hammer, Kathryn A. O'Donnell

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

PROTOCADHERIN 7 (PCDH7), a transmembrane receptor and member of the Cadherin superfamily, is frequently overexpressed in lung adenocarcinoma and is associated with poor clinical outcome. Although PCDH7 was recently shown to promote transformation and facilitate brain metastasis in lung and breast cancers, decreased PCDH7 expression has also been documented in colorectal, gastric, and invasive bladder cancers. These data suggest contextdependent functions for PCDH7 in distinct tumor types. Given that PCDH7 is a potentially targetable molecule on the surface of cancer cells, further investigation of its role in tumorigenesis in vivo is needed to evaluate the therapeutic potential of its inhibition. Here, we report the analysis of novel PCDH7 gain- and loss-of-function mouse models and provide compelling evidence that this cell-surface protein acts as a potent lung cancer driver. Employing a Creinducible transgenic allele, we demonstrated that enforced PCDH7 expression significantly accelerates Kras G12D -driven lung tumorigenesis and potentiates MAPK pathway activation. Furthermore, we performed in vivo somatic genome editing with CRISPR/Cas9 in Kras LSL-G12D ; Tp53 fl/fl (KP) mice to assess the consequences of PCDH7 loss of function. Inactivation of PCDH7 in KP mice significantly reduced lung tumor development, prolonged survival, and diminished phospho-activation of ERK1/2. Together, these findings establish a critical oncogenic function for PCDH7 in vivo and highlight the therapeutic potential of PCDH7 inhibition for lung cancer. Moreover, given recent reports of elevated or reduced PCDH7 in distinct tumor types, the new inducible transgenic model described here provides a robust experimental system for broadly elucidating the effects of PCDH7 overexpression in vivo. Implications: In this study, we establish a critical oncogenic function for PCDH7 in vivo using novel mouse models and CRISPR/Cas9 genome editing, and we validate the therapeutic potential of PCDH7 inhibition for lung cancer.

Original languageEnglish (US)
Pages (from-to)594-603
Number of pages10
JournalMolecular Cancer Research
Volume17
Issue number2
DOIs
StatePublished - Feb 2019

ASJC Scopus subject areas

  • Molecular Biology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Modulation of mutant krasG12D-driven lung tumorigenesis in vivo by gain or loss of PCDH7 function'. Together they form a unique fingerprint.

  • Cite this